Although investors ignored positive data from three Phase III trials of The Liposome Co. Inc.'s Evacet liposomal formulation of doxorubicin to treat metastatic breast cancer, the company is looking at an eventful year end that should include a profitable fourth quarter as well as an NDA filing for Evacet.

The company's first product, Abelcet amphotericin B lipid complex to treat fungal infections, posted $52.9 million in sales in the first nine months of 1998. The company had a net loss for the period of $6.2 million ($0.16), but expects to be profitable going forward through 1999.